Vesigen Therapeutics is a biotechnology company advancing groundbreaking therapies directed to intracellular targets using a fusogenic extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), is expanding the universe of druggable targets by enabling the delivery of a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and gene-editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells. The team is committed to leveraging ARMMs technology to develop transformative medicines and address currently unmet medical needs.

Biotechnology

Vesigen Therapeutics

Paulash Mohsen

Qin Yu

Yashodhan Chinchore

Lorien Moore

Qiyu W.

Gang (Gary) Hao

Joseph Nabhan

The Board Team at Vesigen Therapeutics provides strategic guidance, governance, and oversight to ensure the company effectively advances its pioneering ARMMs technology. Comprised of experienced members from diverse backgrounds, the Board makes critical decisions around corporate strategy, financial planning, regulatory compliance, and partnerships to drive the development of transformative medicines for unmet medical needs.

Board Team

Scientific and Research Team

Business Operations and Development

Board Team

About

Team members

Other teams at Vesigen Therapeutics

Scientific and Research Team

Business Operations and Development